Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Research Article Volume 7 Issue 8

Impella® 5.0 Microaxial Heart Pump Implementation for Prevention of Postcardiotomy Cardiogenic Shock

Alexey Koroteev*

Professor, Moscow Sechenov Medical University, Russia

*Corresponding Author: Alexey Koroteev, Professor, Moscow Sechenov Medical University, Russia.

Received: June 06, 2023; Published: July 05, 2023


Objective: The aim of this study was to assess the efficiency of Impella® 5.0 microaxial catheter-mounted heart pump implementation in prevention of postcardiotomy cardiogenic shock in patients, operated for dilated cardiomyopathy, heart failure, NYHA class III-IV. The AKOR® extracardiac mesh implantation and mitral valve replacement were performed to all of them.

Background: Postcardiotomy cardiogenic shock (PCCS) is associated with high mortality rates of 50-80%. The results of mechanical circulatory support (MCS) in PCCS depend on proper choice of the MCS device and optimal timing of its initiation. The effectiveness of preventive use of Impella® 5.0 microaxial heart pumps after the AKOR® extracardiac mesh implantation and mitral valve replacement in patients with dilated cardiomyopathy, NYHA III-IV was tested.

Patients and Methods: The Impella® 5.0 (Abiomed, Inc.; Danvers, Mass) is a percutaneous ventricle assist device that is positioned across the aortic valve with inflow in the left ventricle (LV) and outflow in the ascending aorta. This configuration augments forward flow and directly decompresses the LV. MCS with the Impella® 5.0 microaxial heart pumps was used preventively in 9 patients (mean age was 61 ± 6 years, all males). Preoperatively all of them were evaluated as high risk of PCCS development. They had idiopathic dilated cardiomyopathy (DCM), mitral valve regurgitation: grade 3,0 ± 0,6, mean NYHA class of 3,0 ± 0,7. Mean LV ejection fraction (EF) was 31,6 ± 6,1%. LV end diastolic volume (LV EDV) was 234 ± 52 ml. Mean pulmonary artery wedge pressure was 27 ± 8 mmHg. Preoperatively cardiac index was a mean of 2,2 ± 0.1 l/min. Mitral valve replacement and the AKOR® extracardiac mesh implantation were performed in all cases. The AKOR® extracardiac mesh was implanted to prevent further dilation of heart chambers. The Impella® 5,0 catheter was inserted and initiated intraoperatively, in post bypass period, to prevent PCCS development.

Results: Cardiac index increased from 2,2 ± 0,1 l/min to 2,5 ± 0.2 l/min/m² (p = 0.003). Mean pulmonary wedge pressure decreased from 27 ± 8 mmHg to 17 ± 4 mmHg (p = 0.003). LV EF increased to 39,2 ± 5,2%. The mean duration of Impella® 5.0 support was 3 ± 1days. There was one case of device-related complications: hemolysis indicated by increase in plasma free hemoglobin developed at the 2d postoperative day in one patient; it was caused by suctioning of the pump and was corrected by its repositioning. No patient suffered from PCCS. All patients survived.

Conclusions: The preventive application of Impella 5.0 is a suitable treatment modality to avoid postcardiotomy cardiogenic shock in patients with compromised myocardium.

 Keywords: Postcardiotomy Cardiogenic Shock; Dilated Cardiomyopathy; AKOR® Extracardiac Mesh; Impella®; Timing of Initiation


  1. Sylvin EA., et al. “Mechanical Support for Postcardiotomy Cardiogenic Shock: Has Progress Been Made?” Journal of Cardiac Surgery 4 (2010): 442-454.
  2. Fukuhara S., et al. “Contemporary Mechanical Circulatory Support Therapy for Postcardiotomy Shock”. The General Thoracic and Cardiovascular Surgery4 (2016): 183-191.
  3. The Task Force for the Diagnosis, Treatment of Acute, Chronic Heart Failure 2012 of the European Society of Cardiology. “Developed in collaboration with the Heart Failure Association (HFA) of the ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012”. European Heart Journal 33 (2012): 1787-1847.
  4. Samuels LE., et al. “Pharmacological criteria for ventricular assist device insertion following postcardiotomy shock: experience with the Abiomed BVS system”. Journal of Cardiac Surgery 14 (1999): 288-293.
  5. Engström AE., et al. “Mechanical Circulatory Support With the Impella 5.0 Device for Postcardiotomy Cardiogenic Shock: A Three-Center Experience”. Minerva Cardioangiology5 (2013): 539-546.
  6. Werdan K., et al. “Mechanical circulatory support in cardiogenic shock”. European Heart Journal3 (2014): 156-167.
  7. Lazkani M., et al. “A retrospective analysis of Impella use in all-comers: 1-year outcomes”. Journal of Interventional Cardiology 6 (2017): 577-583.
  8. Flaherty MP., et al. “Early Initiation of Impella in Acute Myocardial Infarction Complicated by Cardiogenic Shock Improves Survival: A Meta-Analysis”. JACC: Cardiovascular Interventions17 (2017): 1805-1806.
  9. Radovanovic N., et al. “Reductive annuloplasty of double orifices in patients with primary dilated cardiomyopathy”. The Annals of Thoracic Surgery 73 (2002): 751-755.
  10. Gummert JF., et al. “Mitral valve repair in patients with end stage cardiomyopathy: who benefits?”. European Journal of Cardio-Thoracic Surgery 23 (2003): 1017-1022.
  11. Bolling SF., et al. “Early outcome of mitral valve reconstruction in patients with end-stage cardiomyopathy”. The Journal of Thoracic and Cardiovascular Surgery 109 (1995): 676-683.
  12. Griffith BP., et al. “The RECOVER I: a multicenter prospective study of Impella 5.0/LD for postcardiotomy circulatory support”. The Journal of Thoracic and Cardiovascular Surgery 2 (2013): 548–554.
  13. Konstantinov BA., et al. “A new method of surgical treatment of dilated cardiomyopathy”. Khirurgiia (Mosk) (2002).
  14. Belenkov YN., et al. “Mitral valve replacement and implantation of an extracardiac mesh frame in patients with severe heart failure: results of a clinical study and a description of a clinical case 18 years after surgery”. Kardiologiia (2021).


Citation: Alexey Koroteev. “Impella® 5.0 Microaxial Heart Pump Implementation for Prevention of Postcardiotomy Cardiogenic Shock”.Acta Scientific Medical Sciences 7.8 (2023): 29-32.


Copyright: © 2023 Alexey Koroteev. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US